Campbell Bradley L, an insider at Amicus Therapeutics Inc (FOLD), acquired 1,151,869 shares of the biotechnology company on November 23, 2025. The shares were purchased at a price of $9.03 each, bringing the total transaction value to approximately $10.40 million. Following this acquisition, Bradley holds a total of 1,151,869 shares in Amicus.
This transaction adds to the transparency of insider activities at the company, which focuses on developing medicines for metabolic diseases. Amicus Therapeutics, headquartered in Princeton, New Jersey, has a market capitalization of $3.1 billion and is known for its therapies, including Galafold and Pombiliti + Opfolda, aimed at treating conditions such as Fabry disease and late-onset Pompe disease.
Insider buying can often signal confidence in a company's future, as executives typically have access to sensitive information regarding their organization's operations. However, it is essential for investors to consider these transactions as part of a broader analysis, looking at patterns of activity among multiple insiders over time rather than isolated events.
Amicus Therapeutics is set to report its upcoming earnings on April 29, 2026, with an estimated EPS of $0.03 and revenue of $167.9 million, followed by another report on July 29, 2026, where the EPS is expected to rise to $0.06 with revenue projected at $184.7 million.